Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
Date:3/24/2011

REDWOOD CITY, Calif., March 24, 2011 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute or breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2010.

Net loss for the fourth quarter of 2010 was $3.5 million, or $5.23 per common share, compared with a net loss of $3.7 million, or $6.05 per common share, for the fourth quarter of 2009. Net loss for the year ended December 31, 2010 was $14.3 million, or $21.84 per common share, compared to a net loss of $20.1 million, or $34.93 per common share, for the year ended December 31, 2009.

Research and development expenses for the twelve and three months ended December 31, 2010 totaled $8.2 million and $1.9 million, compared to $15.5 million and $2.3 million for the twelve and three months ended December 31, 2009. General and administrative expenses were $4.0 million and $1.0 million for the year and quarter ended December 31, 2010, compared to $3.5 million and $1.0 million for the year and quarter ended December 31, 2009.

As of December 31, 2010, AcelRx had cash, cash equivalents and short-term investments of $3.7 million, compared to $12.5 million as of December 31, 2009. On February 16, 2011, AcelRx closed its initial public offering of 8.0 million shares of common stock resulting in net proceeds to AcelRx of $35.6 million.  We intend to utilize these funds primarily for advancement of our lead program, our hospital-based, patient-controlled analgesia (PCA) product, the Sufentanil NanoTab PCA System (ARX-01).

"We are pleased with our progress towards initiating the Phase 3 program for ARX-01 in acute post-operative pain," said Richard King, President and Chief Executive Officer of AcelRx. "We anticipate
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
2. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
3. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
4. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
7. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
8. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
9. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
10. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015  IRIDEX Corporation (Nasdaq: IRIX ) ... ended January 3, 2015.  , Revenues were $11.8 ... the Company and up 11% from $10.6 million in the ... a record, up 12% from $38.3 million in 2013. ... up from 48.6% in the fourth quarter of the prior ...
(Date:3/5/2015)... 5, 2015  As the pharmaceutical industry works ... & Compliance professionals are placing a significant emphasis ... issued today by LRN, the leader in Ethics ... majority of respondents expressed that clarity on company ... of E&C training programs (57%), trumping understanding of ...
(Date:3/5/2015)... FALLS, N.J. , March 5, 2015 CANTEL ... results for its second quarter ended January 31, 2015 on ... conference call to discuss the results at 11:00 AM ET. ... (877) 407-8033 approximately 5 to 10 minutes before the beginning ... digital replay of the call will be available from Thursday, ...
Breaking Medicine Technology:IRIDEX Reports 2014 Fourth Quarter, Year-End Results 2IRIDEX Reports 2014 Fourth Quarter, Year-End Results 3IRIDEX Reports 2014 Fourth Quarter, Year-End Results 4IRIDEX Reports 2014 Fourth Quarter, Year-End Results 5IRIDEX Reports 2014 Fourth Quarter, Year-End Results 6IRIDEX Reports 2014 Fourth Quarter, Year-End Results 7IRIDEX Reports 2014 Fourth Quarter, Year-End Results 8Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Second Quarter Ended January 31, 2015 2
... tumors (NET) experienced,clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR ... Depot, - 77% of patients with pancreatic NET ... treated with daily RAD001, - Data show RAD001, an ... have limited ...
... Sept. 12 InVitria,( http://www.InVitria.com ), a ... enhance productivity, safety and time to market ... science research and,diagnostics industry, will be an ... and Exhibition in Anaheim, California on September,23-26. ...
Cached Medicine Technology:RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 2RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 3RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 4RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 5RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 6RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors 7InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International 2
(Date:3/6/2015)... California (PRWEB) March 06, 2015 ... one of the most common forms of cancer and ... Breast cancer can be screened through various techniques and ... Mammography however remains the gold standard technique in breast ... as cost, time taken for the procedure, required expertise ...
(Date:3/6/2015)... York, NY (PRWEB) March 06, 2015 Ticket ... tickets . This popular ticket exchange has extended their customer ... hails from Hebden Bridge, West Yorkshire England and he began ... 2005. In the past couple of years Ed Sheeran ... though whenever Ed Sheeran is on stage he is having ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Further solidifying ... , Medical Doctor Associates announced today that the company ... after winning the Best of Staffing Talent Award five ... Inavero’s Best of Staffing Talent Diamond winners are proven ... given to them by the individuals they have helped ...
(Date:3/6/2015)... TN (PRWEB) March 06, 2015 Since ... January 1, 2015, there has been an overwhelming demand ... an efficient and compliant CCM program. The Centers ... on several matters. , PYA’s updated white paper—“ ... this new guidance into a detailed, yet practical “how ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
Breaking Medicine News(10 mins):Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Popularity of 3D Mammography Drives the Global Mammography Equipment Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Ed Sheeran Tickets in Indianapolis, Austin, Albany, St. Louis, London, Des Moines, Salt Lake City, Saskatoon, Regina and Denver/Morrison Now On Sale at Ticket Down 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 2Health News:Cross Country Healthcare: Medical Doctor Associates Earns Inavero's 2015 Best of Staffing Talent Diamond Award 3Health News:Updated PYA White Paper Meets Demand for Guidance on Providing and Billing Medicare for Chronic Care Management 2Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2
... available in German . , Scientists from the ... lived off more than 100 million years ago. They want to ... as they did. In actual fact such gigantic animals should not ... in the journal ,Proceedings of the Royal Society B,. , Take ...
... & Melinda Gates Foundation to ... in 11 new countries, OAK BROOK, Ill., Feb. 6 ... it has received a $24.2 million grant from the Bill ... Micro Insurance Agency, greatly expand its insurance,products to the poor ...
... allayed some panic about suspected cancer-causing agents, such as ... has been developed through the Cancer Control Program at ... University of New South Wales (UNSW) researcher, Professor Bernard ... level of risk is high say, on a ...
... Feb. 6 Parental Alienation Awareness,Organization (PAAO) is beginning ... for April 25th - Parental Alienation Awareness Day., ... until they,experience it, parental alienation awareness was put forth ... The mission of PAAO is to help the ...
... PALO ALTO, Calif., Feb. 6 Jazz,Pharmaceuticals, Inc. (Nasdaq: ... fourth quarter and full year 2007 financial results on ... financial markets. Jazz,Pharmaceuticals will host an investor conference call ... updates on February 13, 2008, at,5:00 p.m. Eastern Time/2:00 ...
... The Female Health Company,(Amex: FHC ) today announced ... the Premarket Approval Application (PMA) it submitted for,its second ... The Center for Devices and Radiological Health (CDRH) received,FHC,s ... Health Company, Inc., The Female Health Company, based ...
Cached Medicine News:Health News:Bonn scientists simulate dinosaur digestion in the lab 2Health News:Bonn scientists simulate dinosaur digestion in the lab 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 2Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 3Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 4Health News:Opportunity International's Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People 5Health News:Reducing cancer panic 2Health News:Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th 2Health News:Jazz Pharmaceuticals, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 13, 2008 2Health News:The Female Health Company Announces FDA Acceptance for Review of Its FC2 Premarket Approval Application 2
... The new, hydrophilic PressureWire Certus ... the latest innovative cardiology tool for ... multivessel disease using Fractional Flow Reserve ... torquability and pushability with a strengthened ...
... The Sound Pro Combination ... table solution, combining the ... the Ultra Pro and ... ideal for OB/GYN, general ...
...
... mecA ASR contains primers and a FAM-labeled probe ... region of the mecA gene. In addition, this ... DNA for an internal control sequence. This ASR ... Texas Red reporter dyes such as the Cepheid ...
Medicine Products: